Biotech M&A Rumor Tracker 2026
Live tracker of biotech/biopharma rumors in 2026 — target, acquirer, reported deal values, status, updates and sources.
Last updated: 04 Feb 2026
Get 2026 biotech M&A rumor updates as they land (free)
The tracker refreshes weekly — the BioBucks newsletter flags new deals and credible rumors daily (in ~5 mins).
Read by 2,000+ VC, BD&L, and public biotech investors. No spam. Unsubscribe anytime.
Rumors
IO Biotech ↔ Exploring sale
RUMOR
21-Jan-2026
Reported value: N/A
|
Status: Company-announced strategic review
Report
— company press release (GlobeNewswire via Nasdaq).
Sun Pharma ↔ Organon
RUMOR
19-Jan-2026
Reported value: ~US$10B
|
Status: Reported / exploring; Sun Pharma called reports “speculative”
Report
— plus Sun Pharma clarification carried by Economic Times.
Sanofi ↔ Ocular Therapeutix
RUMOR
15-Jan-2026
Reported value: ~$3.4B (~$16/share approach; a higher bid rumored)
|
Status: Reported / preparing improved bid; no comment
Report
— citing French outlet La Lettre.
Eli Lilly ↔ Abivax
RUMOR
12-Jan-2026
Reported value: ~US$17.5B
|
Status: Reported (French press) / denied (“noise”; no talks) in follow-up coverage
Report
— per Reuters (re: La Lettre); later Reuters follow-up quotes Abivax CEO dismissing the chatter (20-Jan-2026).
Merck (MSD) ↔ Revolution Medicines
RUMOR
08-Jan-2026
Updated: 25-Jan-2026
Reported value: US$28B–$32B
|
Status: Talks cooled / no longer in discussions (price disagreement); WSJ says talks could restart or another suitor could emerge
Want deal alerts as they land?
The tracker refreshes weekly — the BioBucks newsletter flags new deals and credible rumors daily (in ~5 mins).
Join 2,000+ VC, BD&L, and public biotech investors. No spam. Unsubscribe anytime.